Across TCGA pan-cancer cohorts, MIR3976HG RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of MIR3976HG’s most consistent transcriptional readouts.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where MIR3976HG RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR3976HG is over-expressed in tumor.
UCEC are the cancer types where MIR3976HG tumor–normal differential expression is most reproducible.